Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Richard Morimoto
Northwestern University, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Proteostasis Therapeutics
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
This research is to understand protein homeostatis in cells and organisms (proteostasis), and investigate the basis of proteostasis dysregulation during aging and in disease. The work uses as a model the expression of disease associated, metastable, aggregation-prone proteins in the nematode C. elegans to collapse of the proteostasis machinery, and examines the role of cytoprotective pathways to restore its balance. Professor Morimoto is a founder of Proteostasis Therapeutics, and discloses both remuneration and equity interest from the company, which has the goal of developing novel therapeutics designed to characterize and pharmacologically control the proteostasis network in cells, and which focuses on protein aggregation diseases. While the work included in this proposal examines basic mechanisms relating to proteostasis, the similarity of these studies and the broad goals of Proteostasis Therapeutics suggest the potential for a perceived conflict of interest that should be managed. The company was previously non-publicly traded, but recently went public.
C. elegans Model for Neurodegenerative Diseases of Aging
NA
Filed on August 25, 2016.
Tell us what you know about Richard Morimoto's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Richard Morimoto filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Richard Morimoto | Northwestern University | Conflict of Interest | Proteostasis Therapeutics, Inc. | >$600,000 |
| Richard Morimoto | Northwestern University | Conflict of Interest | Proteostasis Therapeutics, Inc. | $40,000 - $59,999 |
| Richard Morimoto | Northwestern University | Conflict of Interest | Proteostasis Therapeutics | $40,000 - $59,999 |
| Richard Morimoto | Northwestern University | Conflict of Interest | Proteostasis Therapeutics, Inc. | $20,000 - $39,999 |
| Richard Morimoto | Northwestern University | Conflict of Interest | Proteostasis Therapeutics, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.